



MEMORANDUM

Pfizer and D&D Pharmatech sign \$1.24 million research deal to advance oral dual agonist using ORALINK platform – April 17, 2026

Partnership represents over 40% of D&D's annual sales and leverages ORALINK to address major barriers in oral GLP-1 delivery

South Korea-based [D&D Pharmatech](#) signed a \$1.2 million research services agreement with Pfizer [yesterday](#) to advance an oral peptide dual agonist for obesity treatment. The partnership will be built on D&D's proprietary [ORALINK](#) oral peptide technology platform. The seven-and-a-half-month contract runs from April 14, 2026, to November 30, 2026, though D&D notes the actual duration will extend until all milestone-based payments are completed. Payments will be made within 90 days of each completed research service item, and D&D will conduct manufacturing and supply in-house. Notably, the public [KOSDAQ disclosure filing](#) states that the deal represents over 40% of D&D's most recent annual sales.

-- by Kayla Mathieu, Nour Khachemoune, and Kelly Close